BiologicsMD is an early stage therapeutics company that focuses on novel technologies to actively improve bone health. The company has an exclusive worldwide license to develop a patented new biologic, PTH-CBD™, that selectively binds to bone and stimulates new bone growth. The company was founded in 2009 and to date, the company has both raised private equity and has been awarded a $2.3 million research contract from the Department of Defense.
BiologicMD's lead development drug, PTH-CBD™, is focused on helping patients avoid the destructive effects of osteoporosis and other related bone disorders. Preclinical results for the compound are very promising and have demonstrated five times the efficacy of available bisphosphonate treatments and fewer side effects than currently available PTH-based therapeutics. According to the National Osteoporosis Foundation, one in two women and one in four men will be diagnosed with osteoporosis in their lifetime. The disease can have devastating consequences as it weakens bones and causes over 1.5 million osteoporosis patients to suffer a bone fracture every year. Following a hip fracture, one in five patients will die within a year; 30% will need long term care.